about
High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma.Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group reportApplication of stem cell transplant for brain tumors.High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?Late effects in survivors of childhood CNS tumors treated on Head Start I and II protocols.Immunotherapy for pediatric central nervous system tumors.Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.Relapse and outcome patterns of patients with central nervous system mixed malignant germ cell tumors treated without irradiation: Findings from the third international central nervous system (CNS) germ cell tumor (GCT) study.Outcome of young children with high-grade glioma treated with irradiation-avoiding intensive chemotherapy regimens: Final report of the Head Start II and III trials.Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma.High Incidence of Veno-Occlusive Disease With Myeloablative Chemotherapy Following Craniospinal Irradiation in Children With Newly Diagnosed High-Risk CNS Embryonal Tumors: A Report From the Children's Oncology Group (CCG-99702).Phase I study of temozolomide in combination with thiotepa and carboplatin with autologous hematopoietic cell rescue in patients with malignant brain tumors with minimal residual disease.Persistent racial and ethnic differences in location of death for children with cancer.Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma.Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study.Decreased morbidity and mortality of autologous hematopoietic transplants for children with malignant central nervous system tumors: the 'Head Start' trials, 1991-2009.High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumors.Pilot study assessing a seven-day continuous intrathecal topotecan infusion for recurrent or progressive leptomeningeal metastatic cancer.Quality of life and behavioral follow-up study of Head Start I pediatric brain tumor survivors.A retrospective analysis of recurrent intracranial ependymoma.Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols.Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors.Tandem thiotepa with autologous hematopoietic cell rescue in patients with recurrent, refractory, or poor prognosis solid tumor malignancies.Choroid plexus carcinoma in children: the Head Start experience.Neuropsychological functioning of children treated with intensive chemotherapy followed by myeloablative consolidation chemotherapy and autologous hematopoietic cell rescue for newly diagnosed CNS tumors: an analysis of the Head Start II survivors.Brainstem primitive neuroectodermal tumors (bstPNET): results of treatment with intensive induction chemotherapy followed by consolidative chemotherapy with autologous hematopoietic cell rescue.Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue.Utility of MRI versus tumor markers for post-treatment surveillance of marker-positive CNS germ cell tumors.Prospective Feasibility and Safety Assessment of Surgical Biopsy for Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma.Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastomaFair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trialsPre-irradiation intensive induction and marrow-ablative consolidation chemotherapy in young children with newly diagnosed high-grade brainstem gliomas: report of the "head-start" I and II clinical trialsThiotepa-Based High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Recurrent or Progressive CNS Germ Cell TumorsNormalisation of hair follicle morphology in C3H/HeJ alopecia areata mice after treatment with squaric acid dibutylesterSepticemia and septic shock in pediatric patients: 140 consecutive cases on a pediatric hematology-oncology serviceA primary cardiac sarcoma with features of a desmoplastic small round cell tumor in an adolescent malePreoperative chemotherapy to salvage the hand in a case of giant infantile hemangiopericytoma
P50
Q34132773-B0B2FF7A-0157-4C96-BBA6-1D3B11BCAE4EQ35735986-FFDF38A3-1F49-4C3B-93CC-16D6265518CAQ35763907-15A9B183-A1E4-4A93-B3DD-FA4CFCEEDEC6Q35800584-047A5558-9640-4F30-8706-8032FD5F3949Q36069886-849B02F1-096A-474D-AAD4-A646852EDEA7Q36467511-43A6508F-28D5-4451-A07F-4ABF9C7F2CD3Q37629078-3DC1F17E-A033-4559-A982-90B0D2E691EDQ37636027-8AB01ED3-09E9-4C48-970A-3292A8771236Q37670062-CB870994-2ECE-4380-BF14-289A3105CC32Q38520572-58711577-CC21-4E15-A727-F615F51EC51BQ38873292-9088974A-CAE2-4BDF-B460-3CE5A05A9C7CQ39858154-FE89E430-3173-4005-9923-5FB8055C1314Q40744398-375B51AB-375B-46B4-8B5A-8B3E55196C3BQ41003114-65531B34-68CE-4809-A565-4EE01F68F1F2Q41196481-220C6163-7BB3-4474-A69B-0F5B79B5F243Q43058866-486085C3-B0DA-4F16-851F-99854A462731Q43197920-6EDA8571-30F5-4620-8247-94716F7DFABBQ44603483-F8B99252-5D8C-4D92-8C9C-310CE065C983Q44700029-51A325CB-CB0D-4CCC-8999-E300864008CEQ44749323-1310EC68-76D4-4355-8342-86EE32BDBE1AQ44827236-7D63C029-4AE7-451B-ADD2-DDC910777086Q45893600-169B051E-E1A5-4BC9-9548-9802D4A41F76Q45960095-82BFD487-A5CF-4B20-B493-DDE281647DDCQ46001346-AD62C1F5-CD41-4C0B-9FED-51011A5DBE93Q46669775-0AF234F1-8A98-4D47-A7EB-01EDEABD1C44Q48113874-D15464F3-F147-489D-AF84-1E1A3FF5F93DQ48338460-1A7D914C-0270-456B-BD39-F4415A6859E7Q48354967-796A1CF3-CB60-4A48-AF52-54EBCA34F47AQ48410114-1AB66171-8E19-4E75-A3AB-3F076A43CC25Q48460429-9FA5D21B-6BB9-4F52-9DF2-6A590650C98FQ51645948-D5423BCF-43B8-4372-9B01-1C75CF196159Q55456558-2D74F587-2B80-4893-BB2D-3F4697897C59Q56967218-969C43DF-55B7-4186-B232-90724C648D7BQ57443845-7B36C630-50FA-40FB-801F-327FE1EF5DD0Q58614425-054E0C76-66B6-4A31-9D11-0D2267AB241DQ62079249-34DF61F7-EBF0-4FD2-A427-0319996FBA10Q74297612-89391AAA-5C8B-4673-A524-D6E51551495FQ74653883-91793FFE-290C-43B9-8ECA-A277877672B7Q84050612-BB4A580F-355F-4534-BE6C-A5A13FF80B60Q84332866-2C4FF90D-CD73-49F8-BA22-1C937BF8D8D9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sharon Gardner
@ast
Sharon Gardner
@en
Sharon Gardner
@es
Sharon Gardner
@nl
type
label
Sharon Gardner
@ast
Sharon Gardner
@en
Sharon Gardner
@es
Sharon Gardner
@nl
prefLabel
Sharon Gardner
@ast
Sharon Gardner
@en
Sharon Gardner
@es
Sharon Gardner
@nl
P106
P31
P496
0000-0002-8857-5487